Published Online: Saturday, July 1, 2006

A federal district court in Midland, Tex, told the FDA to back away from its controversial efforts to restrict pharmacy's right to compound drugs. The decision makes it clear that compounded preparations are not new, unapproved drugs subject to FDA regulation. It "spares drug-compounding pharmacies from having to meet strict FDA regulations on drug safety and efficacy before they can market their products," according to the International Academy of Compounding Pharmacists (IACP).

Describing the court's action as a "landmark" decision, IACP Executive Director L.D. King said that the ruling stops "FDA's encroachment on the authority of state boards of pharmacy in its tracks, and it ensures that patients and physicians will continue to have access to compounded medicines on which they rely."

Latest Articles
Pharmacies are rated as some of the best places to receive top-notch customer service in America.
Often caused by acid reflux, eosinophilic esophagitis is an emerging inflammatory disease that is generally unresponsive to proton pump inhibitor therapy.
Carlos Aquino, founder and president of PharmaDiversion LLC, discusses timing of inspections from the Drug Enforcement Administration.
The FDA has again rejected AMAG Pharmaceuticals’ application for a single-dose version of hydroxyprogesterone caproate injection (Makena) to reduce the risk of preterm birth for at-risk women.
Latest Issues